Conferences - Seminars
Fusion and connection of classical and new chemical modalities for ‘undruggable’ targets
By Dr. Eric Valeur, AstraZeneca
Eric Valeur is Associate Director for New Modalities at AstraZeneca. He is driving research within the chemical space at the interface of small and large molecules. His present research interests include small molecules, peptides, macrocycles, oligonucleotides and conjugates thereof.
Organization Christian Heinis
Accessibility Informed public